Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Rivaroxaban

Rivaroxaban

Direct oral factor Xa inhibitor (DOAC)

DOACAFVTEAdultHigh Yield

Indication

NVAF β€’ VTE treatment β€’ VTE prophylaxis post-hip/knee replacement β€’ CAD/PAD (low-dose) in some regions

At a glance

INDICATIONS (CORE USE)

NVAF (once daily with evening meal if CrCl >50); VTE (BID Γ—21d then OD); **CrCl 15–50** dose reduction for AF β€” label-critical.

ADULT DOSE (STANDARD)

AF: 20 mg daily with **evening meal** if CrCl >50; **15 mg daily** if CrCl 15–49; VTE: 15 mg BID Γ—21d then 20 mg daily

MAX DOSE

20 mg daily (AF); acute VTE 15 mg BID short course

Route

PO

PEDIATRIC DOSE

Pediatric VTE dosing exists in some regions β€” weight-based β€” specialist

Do not miss

Must-not-miss safety points

Major warning

- **GI bleeding** risk may be higher than some DOACs β€” patient and indication context - Food: **15/20 mg** with meal; absorption depends on dose - CrCl cutoffs change **AF vs VTE** tables β€” do not mix

Indications

USE IF: NVAF, VTE, or labeled orthopedic prophylaxis when renal function fits label. AVOID IF: mechanical valves, severe mitral stenosis, CrCl below threshold, pregnancy.

Primary

  • NVAF stroke prevention
  • DVT/PE treatment and reduction in recurrence

Secondary

  • Hip/knee replacement thromboprophylaxis (duration label-specific)
  • CAD/PAD (2.5 mg BID) where approved

Dosing

STANDARD (ADULT PO)

20 mg daily with evening meal (AF, CrCl >50) β€” verify

ADULT DOSE

**AF:** CrCl >50 β†’ 20 mg daily with dinner; CrCl **15–49** β†’ **15 mg daily** with food. **VTE:** 15 mg BID Γ—21d with food, then 20 mg daily (CrCl >50) or 15 mg daily if CrCl ≀50 β€” **verify SFDA label**. **CrCl <15:** generally avoid.

PEDIATRIC DOSE

If approved: weight-based β€” specialist.

MAX DOSE

Per indication β€” 20 mg daily common ceiling for AF.

Practical Note

Evening meal for high doses; 10 mg tablet can be taken without food (product-specific).

Warnings

Clinical warnings

  • **Major active bleeding** or **high-risk bleeding** site β†’ do not initiate until addressed; hold if bleeding develops
  • **Duplicate anticoagulation** (DOAC + warfarin + LMWH + antiplatelet) β†’ medication reconciliation every transition β€” major bleed setup
  • **Mechanical heart valves** (especially mitral) / **moderate-severe mitral stenosis** / selected APS β†’ DOACs **contraindicated or not preferred** β€” use guideline-based therapy
  • **Pregnancy / breastfeeding** β†’ DOACs generally **avoided** in pregnancy; lactation β€” agent-specific β€” **specialist**
  • Neuraxial anesthesia timing
  • Discontinue before surgery per bleed risk

Adverse effects

  • Bleeding
  • anemia
  • GI upset
  • dizziness

Contraindications

  • **Active pathological / major bleeding** β€” stabilize/reverse per protocol before routine (re)start unless embedded in explicit reversal plan
  • **Upcoming invasive procedure** β€” **do not continue blindly**; document **hold/bridge/switch** with anesthesia/surgery when applicable
  • **Mechanical mitral valve / moderate–severe mitral stenosis / selected APS** β€” **DOAC label restrictions** β€” use guideline-directed alternatives
  • Active major bleeding
  • Hypersensitivity
  • Lesions with high bleed risk untreated

Drug interactions

  • **Strong CYP3A4 + P-gp inhibitor** β†’ **avoid combination** or **switch agent** per label β€” do not rely on β€œmonitor only”
  • **Moderate inhibitor/inducer** β†’ **dose table per label** or **tighter bleed surveillance**
  • **NSAID or second antiplatelet added** β†’ **reassess** if surgery within days; else **clinical bleed monitoring**
  • Combined P-gp + CYP3A4 inhibitors: ketoconazole, ritonavir β€” avoid
  • Strong inducers: efficacy loss
  • NSAIDs, antiplatelets

Special populations

Pediatrics

Pediatric VTE dosing exists in some regions β€” weight-based β€” specialist

Pregnancy

**Pregnancy:** contraindicated. **

Lactation

** avoid.

Renal impairment

Major dose changes at CrCl 15–49 for AF; VTE has separate table. **CrCl scaffold (FMBM β€” titrate to FDA/SFDA label + pharmacy / anticoagulation clinic):** - **CrCl β‰₯50** β†’ once daily vs BID **indication-specific** (AF vs VTE acute/continuation) - **CrCl 10–50** β†’ **15–49** often dose reduction (e.g. AF 15 mg daily) β€” verify VTE vs AF tables - **CrCl <10** β†’ many labels **avoid** or contraindicate β€” **do not extrapolate** across indications

Hepatic impairment

Child-Pugh B/C β€” contraindicated or avoid.

Elderly

Higher bleed risk; renal function decline common.

Administration

Take larger doses **with food**; follow blister calendar for VTE initiation phase.

Monitoring

  • Monitor: - **Escalation β€” GI bleed symptoms:** **Hold** + endoscopy pathway if indicated; **major** β†’ DOAC reversal protocol - **Escalation β€” neuraxial / food:** **15–20 mg** with meals β€” **last-dose time** must be accurate for ASRA - **Starting warfarin for acute VTE** β†’ **parenteral overlap** when indicated β€” **do not stop parenteral prematurely** per guideline - **Low-risk AF elective surgery** β†’ **avoid routine bridging** β€” use thromboembolic risk stratification - Renal function at baseline and during intercurrent illness
  • Recheck: - **What to check + when:** **CrCl** + **correct dose table** (AF vs VTE phase) β€” recheck after illness/contrast or schedule change - **Escalation β€” wrong table / under-dose:** Reassess immediately β€” thrombosis risk - **Procedure or neuraxial in 48–72h** β†’ **reassess anticoagulant plan** β€” DOAC hold windows **β‰ ** warfarin; document last dose time - **Interacting drug added or stopped** β†’ **recheck INR (warfarin) or reassess bleed risk / renal (DOAC)** within **48–72h** - If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)
  • Hold if:
    - **Bleeding, unexplained Hb drop, thunderclap headache, or focal neuro signs** β†’ **hold** anticoagulant + escalate per bleed protocol

Overdose / toxicity

Clinical Picture

β€’ **No bleed:** Hold dose(s) β†’ recheck **renal function** + interactions β†’ resume per label β€’ **Minor bleed:** Hold DOAC β†’ local hemostasis + **CBC** β†’ restart per bleed resolution + pharmacy β€’ **Major bleed:** **DOAC reversal pathway** β€” **4F-PCC** Β± **andexanet** (per label/protocol) + **ICU** + source control + hematology

Immediate Actions

β€’ **No bleed:** Hold β†’ hemodynamic check β†’ recheck labs/meds β†’ **no vitamin K** for anticoagulant effect β€’ **Minor bleed:** Hold β†’ pressure/packing β†’ **CBC** β†’ observe per site risk β€’ **Major bleed:** Stop DOAC β†’ ABCs β†’ type & screen β†’ **call reversal protocol** (**PCC / andexanet**) β†’ **ICU**

Antidote

**Targeted reversal agents:** **Andexanet** (where indicated) and/or **4F-PCC** per protocol β€” **vitamin K does not reverse DOAC** anticoagulation

Decontamination

β€’ **Toxic ingestion (early):** Charcoal if airway protected β€’ **Bleeding patient:** Management by **hemorrhage severity**, not decontamination alone

Escalation

β€’ **Major:** **ICU**; IR/surgery; **PCC/andexanet** per protocol β€’ **Minor:** Observe if high-risk bleed site

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

**AF = once daily with dinner** (if CrCl allows). β†’ **VTE = BID then switch** β€” teach phase. β†’ GI bleed risk β€” counsel melena/hematemesis.

Clinical pearls

Low-dose 2.5 mg BID for CAD/PAD only where label allows β€” not interchangeable with AF dosing. *Anticoagulation (all agents):* **A/B/C bleed tiers** β€” no bleed (hold/adjust) vs minor (hold/protocol) vs major (reversal + ICU/heme). **Warfarin:** high INR without bleed **β‰ ** major-bleed pathway; **PCC + IV K** for life-threatening bleed. **Bridging:** warfarin **slow on/off**; **parenteral overlap** when indicated for acute VTE; **no routine bridge** low-risk AF; **DOAC↔warfarin** table-specific. **Neuraxial:** explicit **last-dose β†’ procedure** documentation. Never extend therapy without indication review.

Anticoagulant safety

  • Food with 15/20 mg
  • CrCl-driven dose
  • Procedure hold

Pharmacokinetics

Oral bioavailability dose-dependent (food enhances high doses); renal elimination ~36%; TΒ½ ~5–9 h.

Mechanism of action

Direct factor Xa inhibitor.

Common brand names

Saudi Arabia

Xarelto, Rivaroxaban

Global

(placeholder β€” verify local prefilled syringe / vial)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • Reversal agents (PCC, andexanet, idarucizumab) availability and dosing vary by hospital β€” follow local protocol.
  • Perioperative interruption and bridging are **indication-specific** β€” do not copy warfarin rules onto DOACs blindly.
  • Switching between anticoagulants requires manufacturer tables + pharmacy to avoid under- or over-anticoagulation.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • CHEST / ACCP antithrombotic guidance (indication-specific)
  • ESC / AHA stroke and anticoagulation guidelines where applicable
  • ASH β€” HIT and VTE resources
  • FDA / SFDA product labeling
  • Institutional anticoagulation service / formulary
  • CHEST / ACCP antithrombotic guidance (indication-specific)
  • ESC / AHA stroke and anticoagulation guidelines where applicable
  • ASH β€” HIT and VTE resources
  • FDA / SFDA product labeling
  • Institutional anticoagulation service / formulary

Do not miss

  • Document indication, target intensity, and planned duration in the chart
  • Reassess renal/hepatic function after AKI, dehydration, or new interacting medications
  • **Wrong table:** AF **once daily** dosing β‰  VTE **BID-then-daily** phase β€” using AF dose for acute VTE risks undertreatment.
  • **CrCl 15–49:** AF **15 mg daily** vs **20 mg** β€” verify label; **<15** often avoid.
  • **Reversal:** Major bleed β†’ **PCC / andexanet** per protocol β€” not warfarin-style reversal alone.
  • **Neuraxial + food:** High doses need food β€” affects β€œlast dose” time for procedure planning.
  • Wrong table (AF vs VTE) β†’ **under- or over-anticoagulation**.
  • CrCl 15–49 β†’ **15 mg AF dose** β€” not 20.
  • **Bridging & transitions (factory scaffold):**
  • **Warfarin** has **delayed onset/offset** β€” do not expect immediate effect or rapid washout like DOACs.
  • **Acute thrombosis** may require **parenteral overlap** when starting/overlapping warfarin or per label β€” **indication-specific**.
  • **Low-risk AF peri-procedure:** **do NOT routinely bridge** β€” stratify thromboembolic risk per guideline/CHEST-style tables.
  • **DOAC ↔ warfarin** switches are **indication- and table-specific** β€” pharmacy + label (valve, APS, renal).
  • **Neuraxial / high-bleed procedure:** document **last dose**, **ASRA/institutional** windows, **restart** only when hemostasis secure.
  • Food with 15/20 mg
  • CrCl-driven dose
  • Procedure hold